Home › Research › Drug development
What have we learned from past failures of investigational drugs for Alzheimer's disease?
Imbimbo BP, Watling M.. Expert opinion on investigational drugs, 2021-12-20
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
Introduction In the last 15 years, huge efforts against Alzheimer's disease (AD) with drugs targeting β-amyloid (Aβ) and tau have produced poor clinical results. Aducanumab, a recently FDA-approved anti-Aβ monoclonal antibody has been greeted with distrust by most experts, hospitals and insurance companies for its level of efficacy and poor tolerability. Area covered We reviewed literature on Alzheimer trials using PubMed, meeting abstracts and ClnicalTrials.gov and discuss what we can learn from past failures of investigational drugs for Alzheimer's disease, especially anti-Aβ and anti-tau drugs.
What this study adds
Evidence grade: Low
This is a narrative review. This review of past Alzheimer's drug trials found that 15 years of efforts targeting β-amyloid and tau produced poor clinical results. The authors state that aducanumab, an anti-Aβ antibody, has been met with distrust by most experts, hospitals and insurance companies because of its level of efficacy and poor tolerability.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Imbimbo, B. P., & Watling, M. (2021). What have we learned from past failures of investigational drugs for Alzheimer's disease? Expert opinion on investigational drugs. https://doi.org/10.1080/13543784.2021.2017881
Vancouver
Imbimbo BP, Watling M. What have we learned from past failures of investigational drugs for Alzheimer's disease? Expert opinion on investigational drugs. 2021. doi:10.1080/13543784.2021.2017881. PMID: 34890262.
BibTeX
@article{imbimbo2021-34890262,
author = {Imbimbo, B. P. and Watling, M.},
title = {{What have we learned from past failures of investigational drugs for Alzheimer's disease?}},
journal = {Expert opinion on investigational drugs},
year = {2021},
doi = {10.1080/13543784.2021.2017881},
pmid = {34890262},
url = {https://doi.org/10.1080/13543784.2021.2017881}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- Aducanumab, a recently FDA-approved anti-Aβ monoclonal antibody has been greeted with distrust by most experts, hospitals and insurance companies for its level of efficacy and poor tolerability.
- Area covered We reviewed literature on Alzheimer trials using PubMed, meeting abstracts and ClnicalTrials.gov and discuss what we can learn from past failures of investigational drugs for Alzheimer's disease, especially anti-Aβ and anti-tau drugs.
- Expert opinion It is our opinion that previous failures of anti-AD drugs suggest that soluble Aβ and tau are not appropriate drug targets.
- In addition, pivotal clinical trials of future clinical candidates should avoid major protocol amendments and futility analyses.
Why it matters
This review of past Alzheimer's drug trials found that 15 years of efforts targeting β-amyloid and tau produced poor clinical results. The authors state that aducanumab, an anti-Aβ antibody, has been met with distrust by most experts, hospitals and insurance companies because of its level of efficacy and poor tolerability.
New to this subject? Start with our plain-English guide: Treatments →
Study details
- Evidence strengthLow
How this study scored 34/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Expert opinion on investigational drugs) |
| Journal's citation record | 1 / 4 | Expert Opinion on Investigational Drugs: journal h-index 132 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 3 / 5 | 2021 — within 6 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 3 / 7 | Cited 23 times (OpenAlex, 2026-10-10) |
| Citations per year | 2 / 5 | 3.3 citations a year over 7 year(s) since 2021 |
| Impact for its field and year | 2 / 6 | Cited 2.6× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 1 / 4 | Cited 11 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 2 / 4 | Last-listed author Mark I L Watling: h-index 21 (OpenAlex, whole career) |
| Institution's track record | 0 / 3 | Chiesi (Italy): institution h-index 115 (OpenAlex) |
| Multicenter collaboration | 0 / 3 | OpenAlex lists 1 institution(s) in 1 country — scores zero (affiliation lists can be incomplete) |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 34890262) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Total | 34 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
May need a subscription OpenAlex found no free copy of the full text (checked 6 Feb 1020), so the publisher may charge for it. The PubMed abstract is free.
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 20.
Related studies in Drug development from nearby years
Also in Drug development
104 studies in the library are filed under Drug development with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The Drug development hub.